BAN0805 – Parkinson’s disease

The drug candidate BAN0805 (previously ABBV-0805) is a monoclonal antibody that selectively binds and eliminates oligomers and protofibrils of alpha-synuclein. The goal is to develop a disease modifying treatment that stops or slows down disease progression.

In the Parkinson’s disease treatment area, BioArctic has been collaborating with AbbVie since 2016 when a research agreement was entered into. AbbVie was granted the option to license the right to develop and commercialize BioArctic’s portfolio of antibodies against alpha-synuclein for Parkinson’s disease and other potential indications.

At the end of 2018, AbbVie exercised this option. AbbVie’s option to license the portfolio was effective after clearance by the U.S. Antitrust legislation at the end of 2018. In February 2019 FDA approved the application to conduct a clinical study with BAN0805 and the Phase 1 study started in March 2019. At the International Congress of Parkinson’s Disease and Movement Disorders® (MDS) in September 2021, BioArctic presented preclinical results and AbbVie presented results from the Phase 1 study that support continued development of the antibody.

On April 20, 2022, AbbVie informed BioArctic that it had taken a strategic business decision to terminate the collaboration regarding BioArctic’s alpha-synuclein portfolio. BioArctic is currently working with AbbVie to transfer the projects back with the aim of finding a new partner.

The scope of the drug candidate BAN0805 may be expanded to include, for example, Lewy body dementia and multiple system atrophy.

The project is based on research from Uppsala University in Sweden.